胜利广场技术使收入翻了一番,保持盈利,并在2025年Q3扩大了保健举措。 Victory Square Technologies doubled revenue, stayed profitable, and expanded health initiatives in Q3 2025.

胜利广场技术报告,2025年Q3成果强劲,Hydright Technologies全年收入翻了一番,连续第四季度盈利,在美国50个州维持一个符合要求的临床网络,并预测2025财政年度有110多万份产品订单。 Victory Square Technologies reported strong Q3 2025 results, with Hydreight Technologies doubling revenue year-over-year and achieving its fourth consecutive profitable quarter, maintaining a compliant clinical network across all 50 U.S. states and projecting over 1.1 million product orders for fiscal year 2025. 该公司推出了1 000万美元的数字保健和长寿加速器,推进了2026年首次人类研究的口服胰岛素片开发工作,并启动了1 000万美元的宠物健康风险基金。 The company launched a $10 million digital health and longevity accelerator, advanced its oral insulin tablet development for first-in-human studies in 2026, and launched a $10 million pet wellness venture fund. 胜利广场以2 591万美元的现金和有价证券结束季度,强调在美国保健支出不断上升的情况下,它的战略重点是高增长部门。 Victory Square ended the quarter with $25.91 million in cash and marketable securities, emphasizing its strategic focus on high-growth sectors amid rising U.S. healthcare spending.